Reply: Immunosuppression Does Not Reduce Antitumor Efficacy.
作者信息
Mahmood Syed S, Sullivan Ryan J, Reynolds Kerry L, Neilan Tomas G
出版信息
J Am Coll Cardiol. 2018 Aug 7;72(6):702. doi: 10.1016/j.jacc.2018.06.005.
Abstract
摘要
相似文献
1
Reply: Immunosuppression Does Not Reduce Antitumor Efficacy.回复：免疫抑制不会降低抗肿瘤疗效。
J Am Coll Cardiol. 2018 Aug 7;72(6):702. doi: 10.1016/j.jacc.2018.06.005.
2
Immunosuppression Does Not Reduce Antitumor Efficacy.免疫抑制不会降低抗肿瘤疗效。
J Am Coll Cardiol. 2018 Aug 7;72(6):701. doi: 10.1016/j.jacc.2018.04.087.
3
[Myocarditis].[心肌炎]
Rev Med Interne. 2017 Aug;38(8):531-538. doi: 10.1016/j.revmed.2016.12.022. Epub 2017 Feb 2.
4
Treatment of inflammatory dilated cardiomyopathy and (peri)myocarditis with immunosuppression and i.v. immunoglobulins.采用免疫抑制及静脉注射免疫球蛋白治疗炎症性扩张型心肌病和（围）心肌炎。
Herz. 2004 Sep;29(6):624-36. doi: 10.1007/s00059-004-2628-7.
5
Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression.联合免疫抑制时代的巨细胞心肌炎的诊断、治疗和结局。
Circ Heart Fail. 2013 Jan;6(1):15-22. doi: 10.1161/CIRCHEARTFAILURE.112.969261. Epub 2012 Nov 13.
6
Immunosuppression and beta-blockade in heart failure.心力衰竭中的免疫抑制与β受体阻滞剂
Cardiol Clin. 1989 Feb;7(1):171-81.
7
Acute viral myocarditis: role of immunosuppression: a prospective randomised study.
Cardiol Young. 2010 Oct;20(5):509-15. doi: 10.1017/S1047951110000594. Epub 2010 Jun 28.
8
Immunosuppression for myocarditis.心肌炎的免疫抑制治疗。
Lancet. 1989 Jan 14;1(8629):97. doi: 10.1016/s0140-6736(89)91449-9.
9
Myocarditis, histology, and immunosuppression.心肌炎、组织学与免疫抑制。
Lancet. 1988 Nov 26;2(8622):1233-4.
10
Usefulness of Rabbit Anti-thymocyte Globulin in Patients With Giant Cell Myocarditis.兔抗胸腺细胞球蛋白在巨细胞性心肌炎患者中的应用价值
Am J Cardiol. 2015 Aug 1;116(3):447-51. doi: 10.1016/j.amjcard.2015.04.040. Epub 2015 May 8.
引用本文的文献
1
Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis.重新引入免疫疗法治疗免疫检查点抑制剂介导心肌炎后存活的患者。
Clin Res Cardiol. 2021 Jan;110(1):50-60. doi: 10.1007/s00392-020-01648-3. Epub 2020 Apr 15.
本文引用的文献
1
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action.免疫检查点抑制剂相关心肌炎：数据缺口的专家共识与行动呼吁
Oncologist. 2018 Aug;23(8):874-878. doi: 10.1634/theoncologist.2018-0157. Epub 2018 May 25.
2
Immune Checkpoint Inhibitor-Associated Myocarditis.免疫检查点抑制剂相关性心肌炎。
Oncologist. 2018 Aug;23(8):879-886. doi: 10.1634/theoncologist.2018-0130. Epub 2018 May 25.
3
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.免疫检查点抑制剂治疗患者的心肌炎。
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764. doi: 10.1016/j.jacc.2018.02.037. Epub 2018 Mar 19.
4
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.尼伏鲁单抗单药治疗的安全性概况：晚期黑色素瘤患者的汇总分析。
J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14.
5
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.纪念斯隆凯特琳癌症中心接受伊匹单抗治疗的黑色素瘤患者的免疫相关不良事件、全身免疫抑制需求及其对生存和治疗失败时间的影响
J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.
Zotero 插件